Finance

Lists
600664:SHA
Harbin Pharmaceutical Group Co Ltd
CNÂ¥6.99
-1.96%
(-0.14) 1D
Sep 11, 3:00:03 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600664...
Open
CNÂ¥7.06
High
CNÂ¥7.18
Low
CNÂ¥6.92
Mkt. cap
17.96B
Avg. vol.
399.26M
Volume
273.68M
P/E ratio
34.37
52-wk high
CNÂ¥9.51
52-wk low
CNÂ¥2.84
EPS
CNÂ¥0.20
Shares outstanding
2.54B
No. of employees
10K
Open
CNÂ¥7.06
High
CNÂ¥7.18
Low
CNÂ¥6.92
Mkt. cap
17.96B
Avg. vol.
399.26M
Volume
273.68M
P/E ratio
34.37
52-wk high
CNÂ¥9.51
52-wk low
CNÂ¥2.84
EPS
CNÂ¥0.20
Shares outstanding
2.54B
No. of employees
10K
Profile
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate. The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
About Harbin Pharmaceutical Group Co Ltd
CEO-
Employees10K
Founded1988
Headquarters-
SectorPharmaceutical industry
Websitehayao.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.90B
3.94B
4.18B
4.12B
Cost of goods sold
2.95B
2.96B
3.17B
2.94B
Cost of revenue
2.95B
2.96B
3.17B
2.94B
Research and development expenses
33.63M
51.31M
27.02M
33.38M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
753.48M
815.96M
721.16M
807.97M
Operating expense
838.57M
897.00M
786.62M
878.73M
Total operating expenses
3.78B
3.85B
3.96B
3.82B
Operating income
112.30M
88.76M
219.91M
303.13M
Other non operating income
468.22K
-13.01M
-7.97M
-8.68M
EBT including unusual items
119.12M
91.70M
206.43M
311.43M
EBT excluding unusual items
109.94M
63.73M
208.13M
290.47M
Income tax expense
41.30M
34.62M
45.36M
63.42M
Effective tax rate
34.67%
37.75%
21.97%
20.37%
Other operating expenses
24.67M
29.19M
21.94M
31.09M
Net income
68.89M
33.00M
161.13M
249.19M
Net profit margin
1.77%
0.84%
3.86%
6.05%
Earnings per share
-
-
-
-
Interest and investment income
4.05M
3.14M
4.20M
6.12M
Interest expense
-11.05M
-10.76M
-8.01M
-10.10M
Net interest expenses
-7.00M
-7.62M
-3.81M
-3.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
166.37M
143.03M
274.17M
362.05M
Gain or loss from assets sale
3.99M
-3.83M
-
-35.83M
AI content may include mistakes. Learn more
Google apps